First human trial for new mono vaccine begins
NCT ID NCT06908096
Summary
This study is testing the safety of two new experimental vaccines designed to prevent infection with Epstein-Barr virus (EBV), which causes mononucleosis ('mono') and is linked to certain cancers. Researchers are enrolling 750 healthy adults aged 18-29, both those who have never had EBV and those who have. Participants will receive three shots over several months and be closely monitored for side effects and immune responses for about 17 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.